Chapters

Transcript

Video

Although the CAHtalyst trials establish that you can improve 17-hydroxprogesterone and androstenedione levels while lowering the glucocorticoid dose, can we predict long-term benefits?

Although the CAHtalyst trials establish that you can improve 17-hydroxprogesterone and androstenedione levels while lowering the glucocorticoid dose, can we predict long-term benefits?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Perrin White, MD

Perrin White, MD

Chief, Division of Pediatric Endocrinology
Audre Newman Rapoport Distinguished Chair in Pediatric Endocrinology
UT Southwestern Medical Center
Dallas, TX